Translating Prognostic and Predictive Biomarkers into Clinic
Conference Recording Jan 07, 2013
About the SpeakerDr. Mao Mao is Research Fellow leading oncology biomarker effort at Pfizer. He is also President of Asian Cancer Research Group, a not-for-profit organization jointly established by Eli Lilly, Merck and Pfizer. He was Director of Molecular Profiling & Pharmacogenomics at Merck. He was Associate Professor at Shanghai Second Medical University and one of the founding members of the National Human Genome Center in Shanghai.
The advances of genomics technologies have allowed us to characterize cancer at molecular level and to generate biomarkers that can predict how individual cancer patients will progress and respond to certain treatments. In this presentation, I will discuss the ongoing efforts for biomarker discovery, validation and translation, the challenges we are facing, and several successes that have guided clinical practice including MammaPrint testing for breast cancer prognosis and treatment decisions and ALK fusion screening as companion diagnostics for Crizotinib treatment.
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018